June 8th, 2024The Chondrosarcoma Foundation was the first foundation to be inducted into the NORD IAMRARE Patient Registry 2.0 platform and the 44th Foundation to have a Patient Registry in the platform itself. We were approved by NorthStar IRB in early February...
Read ArticleMay 13th, 2024The Chondrosarcoma (CS) Foundation will commemorate its fourth anniversary by continuing to educate the public about this rare bone cancer, advocate for patients fighting the disease and will report on a global natural history study. On May 14,...
Read ArticleMay 2nd, 2024Rapamycin causes growth arrest and inhibition of invasion in human chondrosarcoma cells Jian Song1, Xiaobo Wang2, Jiaxue Zhu3, Jun Liu4 1Department of Orthopaedics, Shandong Jining No.1 People’s Hospital, Jining, Shandong, 272000, China;...
Read ArticleApril 24th, 2024Daniel Brian Hurley, M.D. passed away August 3, 2023, from dedifferentiated chondrosarcoma at age 50 surrounded by his loved ones. His wife Traci and their three kids Rachel, Sam, and Sarah were the light of his life. His family, including his...
Read ArticleApril 24th, 2024Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,...
Read ArticleApril 24th, 2024Ryan A Denu 1, Richard K Yang 2, Alexander J Lazar 2 3, Shalin S Patel 4, Valerae O Lewis 4, Jason Roszik 5, J Andrew Livingston 1, Wei-Lien Wang 2, Kenna R Shaw 6, Ravin Ratan 1, Maria A Zarzour 1, Justin Bird 4, Shaan Raza 7, Kadir C Akdemir 7,...
Read ArticleApril 22nd, 2024Genomic sequencing is a promising tool for expanding the treatment options for chondrosarcoma patients. Genomic sequencing technologies are capable of characterizing known and novel clinically relevant biomarkers, like IDH1/2, and is becoming a...
Read ArticleApril 4th, 2024Abstract This review provides an overview of histopathology, clinical presentation, molecular pathways, and potential new systemic treatments of high-grade chondrosarcomas (CS), including grade 2–3 conventional, dedifferentiated, and mesenchymal...
Read Article